Clinical trials: Acromegaly
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Acromegaly
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour).
- Trial name
- SAGIT Pilot (NCT02231593)
- Testing
- SAGIT
- Where
- 21 sites in United States, Brazil and 5 more
- Volunteers
- 71 people
- Sponsor
- Ipsen
Acromegaly
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg with lanreotide 40mg PR in subjects with active acromegaly.
- Trial name
- LANTERN (NCT02493517)
- Testing
- Lanreotide Autogel®, Lanreotide Acetate
- Where
- 10 sites in China
- Volunteers
- 128 people
- Sponsor
- Ipsen
Acromegaly
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.
- Trial name
- NCT01295060
- Testing
- Octreotide
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy
- Trial name
- NCT00376064
- Testing
- Octreotide acetate and cabergoline/Octrotide and Somavert
- Where
- 16 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog…
- Trial name
- ASTERIA (NCT07037420)
- Testing
- ALXN2420
- Where
- 6 sites in United States, Italy and 2 more
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acromegaly
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
- Trial name
- NCT07583563
- Testing
- Octreotide subcutaneous depot
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Camurus AB
Acromegaly
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
The study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with Lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to…
- Trial name
- ACRO-OPTIM (NCT02698384)
- Where
- 10 sites in France
- Volunteers
- 4 people
- Sponsor
- Ipsen
Acromegaly
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
The objective of this study is to evaluate, in acromegalic patients with disease persistence after surgery who are treated with somatostatin analogues, the histopathological, clinical, morphological and biochemical factors which…
- Trial name
- ESPORA (NCT00500227)
- Where
- 30 sites in Spain
- Volunteers
- 55 people
- Sponsor
- Ipsen
Acromegaly
Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
The primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the…
- Trial name
- ACROSCREEN (NCT02020967)
- Testing
- Non-interventional cross-sectional survey
- Where
- 2 sites in Russia
- Volunteers
- 367 people
- Sponsor
- Ipsen
Acromegaly
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
The purpose of this study is to evaluate the effectiveness in IGF-1 control of lanreotide Autogel (ATG) 120 mg at extended dosing intervals (EDIs) (>4 weeks) in subjects with acromegaly in daily clinical practice.
- Trial name
- SOMACROL (NCT02807233)
- Where
- 39 sites in Portugal, Spain
- Volunteers
- 115 people
- Sponsor
- Ipsen
Acromegaly
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly…
- Trial name
- SODA (NCT00686348)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Ipsen
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with…
- Trial name
- PATHFNDR-2 (NCT05192382)
- Testing
- Paltusotine
- Where
- 57 sites in United States, Argentina and 13 more
- Volunteers
- 111 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of…
- Trial name
- NCT05761431
- Testing
- SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00225979
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide
- Trial name
- NCT00234520
- Where
- 33 sites in Belgium, Czechia and 8 more
- Volunteers
- 225 people
- Sponsor
- Ipsen
Acromegaly
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.
- Trial name
- NCT00642421
- Testing
- C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
- Where
- 10 sites in United States, Belarus and 4 more
- Volunteers
- 40 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
The purpose of the protocol, is to evaluate if lanreotide Autogel 120 mg is effective in the control of Growth Hormone (GH) secretion in patients with active acromegaly.
- Trial name
- NCT00499993
- Testing
- lanreotide (Autogel formulation), duration of treatment 46-48 weeks
- Where
- 24 sites in Italy
- Volunteers
- 63 people
- Sponsor
- Ipsen
Acromegaly
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
The purpose of this study is to evaluate the efficacy of octreotide acetate to decrease GH and IGF-I levels in acromegalic patients, with microadenomas (≤ 10 mm) or macroadenomas (> 10 mm).
- Trial name
- NCT00242541
- Testing
- Octreotide acetate
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals